A detailed history of Vanguard Group Inc transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,766,343 shares of NAUT stock, worth $4.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,766,343
Previous 2,723,596 1.57%
Holding current value
$4.79 Million
Previous $6.37 Million 23.71%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.24 - $3.08 $95,753 - $131,660
42,747 Added 1.57%
2,766,343 $7.88 Million
Q2 2024

Aug 13, 2024

SELL
$2.22 - $3.0 $301,489 - $407,418
-135,806 Reduced 4.75%
2,723,596 $6.37 Million
Q1 2024

May 10, 2024

BUY
$2.41 - $3.18 $71,345 - $94,140
29,604 Added 1.05%
2,859,402 $8.41 Million
Q4 2023

Feb 14, 2024

BUY
$2.34 - $3.39 $50,574 - $73,268
21,613 Added 0.77%
2,829,798 $8.46 Million
Q3 2023

Nov 14, 2023

BUY
$2.87 - $3.94 $18,020 - $24,739
6,279 Added 0.22%
2,808,185 $8.87 Million
Q2 2023

Aug 14, 2023

SELL
$2.21 - $4.52 $84,631 - $173,093
-38,295 Reduced 1.35%
2,801,906 $10.8 Million
Q1 2023

May 15, 2023

BUY
$1.67 - $2.77 $1.11 Million - $1.84 Million
664,825 Added 30.56%
2,840,201 $7.87 Million
Q4 2022

Feb 10, 2023

SELL
$1.55 - $2.47 $2,035 - $3,243
-1,313 Reduced 0.06%
2,175,376 $3.92 Million
Q3 2022

Nov 14, 2022

SELL
$1.96 - $3.13 $7,116 - $11,365
-3,631 Reduced 0.17%
2,176,689 $4.61 Million
Q2 2022

Aug 12, 2022

SELL
$2.64 - $4.84 $453,063 - $830,616
-171,615 Reduced 7.3%
2,180,320 $5.87 Million
Q1 2022

May 13, 2022

BUY
$3.5 - $5.3 $3.73 Million - $5.65 Million
1,066,638 Added 82.99%
2,351,935 $10.2 Million
Q4 2021

Feb 14, 2022

BUY
$4.45 - $6.21 $3.11 Million - $4.34 Million
699,435 Added 119.39%
1,285,297 $6.66 Million
Q3 2021

Nov 12, 2021

BUY
$6.14 - $10.1 $3.6 Million - $5.92 Million
585,862 New
585,862 $3.6 Million

Others Institutions Holding NAUT

About Nautilus Biotechnology, Inc.


  • Ticker NAUT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,663,000
  • Market Cap $216M
  • Description
  • Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...
More about NAUT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.